Incyte Corp (INCY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.67 is considered Undervalued compared with the five-year average of 18.90. The fair price of Incyte Corp (INCY) is between 119.66 to 209.35 according to relative valuation method. Compared to the current price of 100.04 USD , Incyte Corp By Undervalued By 16.39%.

Relative Value

Fair Zone

119.66-209.35

Current Price：100.04

16.39%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Incyte Corp (INCY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Incyte Corp (INCY) has a current Price-to-Book (P/B) ratio of 4.28. Compared to its 3-year average P/B ratio of 3.42, the current P/B ratio is approximately 25.04% higher. Relative to its 5-year average P/B ratio of 4.02, the current P/B ratio is about 6.45% higher. Incyte Corp (INCY) has a Forward Free Cash Flow (FCF) yield of approximately 6.01%. Compared to its 3-year average FCF yield of 3.51%, the current FCF yield is approximately 71.14% lower. Relative to its 5-year average FCF yield of 3.49%, the current FCF yield is about 72.49% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for INCY competitors is 37.85, providing a benchmark for relative valuation. Incyte Corp Corp (INCY.O) exhibits a P/S ratio of 3.70, which is -90.23% above the industry average. Given its robust revenue growth of 27.84%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of INCY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of INCY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is INCY currently overvalued or undervalued?

What is Incyte Corp (INCY) fair value?

INCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Incyte Corp (INCY) is between 119.66 to 209.35 according to relative valuation method.

How does INCY's valuation metrics compare to the industry average?

The average P/S ratio for INCY's competitors is 37.85, providing a benchmark for relative valuation. Incyte Corp Corp (INCY) exhibits a P/S ratio of 3.70, which is -90.23% above the industry average. Given its robust revenue growth of 27.84%, this premium appears sustainable.

What is the current P/B ratio for Incyte Corp (INCY) as of Mar 03 2026?

As of Mar 03 2026, Incyte Corp (INCY) has a P/B ratio of 4.28. This indicates that the market values INCY at 4.28 times its book value.

What is the current FCF Yield for Incyte Corp (INCY) as of Mar 03 2026?

As of Mar 03 2026, Incyte Corp (INCY) has a FCF Yield of 6.01%. This means that for every dollar of Incyte Corp's market capitalization, the company generates 6.01 cents in free cash flow.

What is the current Forward P/E ratio for Incyte Corp (INCY) as of Mar 03 2026?

As of Mar 03 2026, Incyte Corp (INCY) has a Forward P/E ratio of 13.67. This means the market is willing to pay $13.67 for every dollar of Incyte Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Incyte Corp (INCY) as of Mar 03 2026?

As of Mar 03 2026, Incyte Corp (INCY) has a Forward P/S ratio of 3.70. This means the market is valuing INCY at $3.70 for every dollar of expected revenue over the next 12 months.

INCY Valuation